Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Orpro Therapeutics
OrPro Therapeutics develops recombinant thioredoxin for cystic fibrosis treatment.
Sector
Subsector
Keywords
Location
total rounds
total raised
Ziopharm oncology
ZIOPHARM Oncology is a biotechnology company developing gene therapy, cell therapy, and cancer immunotherapy products.
Sector
Subsector
Keywords
Location
total rounds
total raised
Xilio Therapeutics
Xilio Therapeutics develops targeted immuno-oncology therapeutics.
Sector
Subsector
Keywords
Location
total rounds
total raised
GPCR Therapeutics
GPCR Therapeutics USA is a biotechnology company that develops innovative therapeutics targeting cancer.
Sector
Subsector
Location
total rounds
M&A Details1
Financials
Funding Rounds7
Number of Funding Rounds
Money Raised
Their latest funding was raised on 05.02.2015. Their latest round Post-IPO Equity
RUSNANO
RUSNANO is a state-owned investment fund focused on commercializing new technologies in the nanotechnology industry.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors6
Number of lead investors
Number of investors
Endeavour Vision
Endeavour Vision is a private equity firm that invests in growth-stage MedTech and digital health companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Olivier Valdenaire
Olivier Valdenaire, Ph.D., is the Chief Executive Officer of Lumavita AG. Olivier Valdenaire serves as the Chief Executive Officer at Flamentera AG. He also acts as a Consultant to various projects and companies. Olivier Valdenaire served as a Venture Partner at Endeavour Vision SA. Olivier Valdenaire joined in June 2007 in the biotech investment practice within life sciences. He was responsible for all new biotech investments of the firm. Before joining the Endeavour Vision team on a full-time basis, Olivier Valdenaire was sharing his time between real estate activities and biotech and pharmaceutical consulting. He also privately made a number of investments in start-ups. Previously, Olivier Valdenaire served as an Entrepreneur-In-Residence at EMBL Ventures GmbH. Olivier Valdenaire Co-Founded Axovan in 2000 and served as the Chief Executive Officer until acquired in the end of 2003. Prior to his entry into the venture capitalist community, he was an entrepreneur. He also serves on the Board of Flamentera. Olivier Valdenaire held various research positions at INSERM and Hoffmann-La Roche. He was a Researcher in the cardiovascular department of Hoffmann-La Roche (Basel). He serves as a Director of Lumavita AG. He served as an Observer to the Board of Endotis Pharma SA. Olivier Valdenaire familiarized himself with drug development, whilst at the same time, becoming a specialist of the endothelin system. Olivier Valdenaire is a trained biologist with a background in mathematics and physics. He obtained a Ph.D. in Neurobiology from at the Institute for Neurodegeneration in Paris (XI) University after having worked on the dopaminergic system, both in a CNRS laboratory and at the Collège de France. Olivier Valdenaire graduated from the “Ecole des Mines de Paris” (non-specialized executive engineers).
current job
Sven Lingjaerde
Sven started his career over three decades ago at Genevest SA, the oldest private investment firm in Switzerland and spearheaded in 2019 its evolution into Reference Capital where he is currently Managing Partner. Prior to that, he was co-Founder and Managing Partner of Endeavour Vision SA , the leading European Growth Stage Medtech investment firm. In 1997, Sven co-founded Vision Capital, a Trans-Atlantic venture capital firm with offices in Silicon Valley and Geneva. In 2004, he co-founded Euro Private Equity Advisors, a gatekeeper for Pension Funds focusing on Private Equity investments acquired by Natixis Bank in 2013 and rebranded Flexstone Partners in 2019 when it had AUM $7.3bn and 300+ Funds in portfolios. Through his leadership, Reference Capital developed an outstanding track record of early to late stage investments in high tech and biotech private investments on both sides of the Atlantic. Over three decades, Sven has developed an extensive network globally. This network of contacts was consolidated through his founding of the “Tech Tour” organization in 1998. Since then, this initiative has helped many European scale-up companies to accelerate their international growth. Sven has been recognized for his contribution in shaping the European Tech and Life Sciences ecosystem through a number of industry awards (Time Magazine, Investor AllStars, Innovate Europe). Sven studied business administration at HEC, Lausanne, Switzerland and graduated from the ECADE business school, also in Lausanne. He is a member of the YPO-WPO organisation, the premier global leadership network and is the former YPO Alpine chapter's Chairman. A keen skier and golfer, Sven is married and has three children. He is a former Norwegian citizen, became Swiss in 1972 and completed his time in the army as a first lieutenant in the armored forces.
current job
ARCH Venture Partners
ARCH Venture Partners is a venture capital firm that specializes in investing in early-stage technology companies in the United States.
Sector
Subsector
Location
count Of Investments
count Of Exists
Flagship Pioneering
Flagship Pioneering creates and grows ventures to transform health and sustainability.
Sector
Subsector
Location
count Of Investments
count Of Exists
Noubar Afeyan
Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm's VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
current job
People
Founders2
Robert Langer
Robert Langer is the David H.Koch Institute Professor at the Massachusetts Institute of Technology (MIT) (being an Institute Professor is the highest honor that can be awarded to a faculty member). Robert has written over 1,100 articles. Robert also has approximately 760 issued and pending patents worldwide.Robert’s patents have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotechnology and medical device companies. Robert served as a Member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest Advisory Board, from 1995 to 2002 and as its Chairman of the Board of Directors from 1999 to 2002. Robert has received over 180 major awards, including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 2008 Millennium Prize, the world’s most prestigious technology prize. Robert is also the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Robert has received are the Dickson Prize for Science (2002); the Heinz Award for Technology, Economy and Employment (2003); the Harvey Prize (2003); the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright); the General Motors Kettering Prize for Cancer Research (2004); the Dan David Prize in Materials Science (2005); the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research; induction into the National Inventors Hall of Fame (2006); the Max Planck Research Award (2008); and the Prince of Asturias Award for Technical and Scientific Research (2008). In 1998, Robert received the Lemelson-MIT prize, the world’s largest prize for invention for being “one of history’s most prolific inventors in medicine.” In 1989 Robert was elected to the Institute of Medicine of the National Academy of Sciences and in 1992 he was elected to both the National Academy of Engineering and the National Academy of Sciences. Robert is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction. Forbes magazine (1999) and Bio World (1990) have named Robert as one of the 25 most important individuals in biotechnology in the world. Discover magazine (2002) named him as one of the 20 most important people in this area. Forbes magazine (2002) selected Robert as one of the 15 innovators worldwide who will reinvent our future. Time magazine and CNN (2001) named Robert as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America’s Best). Parade magazine (2004) selected Robert as one of six “Heroes whose research may save your life.” Robert has received honorary doctorates from Harvard University, the Mt. Sinai School of Medicine, Yale University, the ETH (Switzerland), the Technion (Israel), the Hebrew University of Jerusalem (Israel), the Universite Catholique de Louvain (Belgium), Rensselaer Polytechnic Institute, Willamette University, the University of Liverpool (England), the University of Nottingham (England), Albany Medical College, Pennsylvania State University, Northwestern University, and Uppsala University (Sweden), and he received the University of California–San Francisco Medal. Robert urrently serves as a Member of the Board of Directors of Advanced Cell Technology and previously served as a Member of the Board of Directors at Momenta Pharmaceuticals from 2001 to 2009, Wyeth from 2004 to 2009, Fibrocell Science, Inc. from 2010 to 2012 and Millipore Corp from 2009 to 2010. Robert received his Bachelor’s Degree from Cornell University in 1970 and his ScD from the Massachusetts Institute of Technology in 1974, both in chemical engineering.
current job
organization founded
Robert Langer
Noubar Afeyan
Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm's VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
current job
Noubar Afeyan